Global Human Insulin Market Growth 2023-2029

Global Human Insulin Market Growth 2023-2029

Human insulin is the name which describes synthetic insulin which is laboratory grown to mimic the insulin in humans.

LPI (LP Information)' newest research report, the “Human Insulin Industry Forecast” looks at past sales and reviews total world Human Insulin sales in 2022, providing a comprehensive analysis by region and market sector of projected Human Insulin sales for 2023 through 2029. With Human Insulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Insulin industry.

This Insight Report provides a comprehensive analysis of the global Human Insulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Insulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Human Insulin market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Insulin and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Insulin.

The global Human Insulin market size is projected to grow from US$ 54630 million in 2022 to US$ 104510 million in 2029; it is expected to grow at a CAGR of 104510 from 2023 to 2029.

In 2018, North America is estimated to dominate the global human insulin market. The Asia-Pacific market is poised to grow the fastest, during the forecast period, owing to growing diabetes prevalence in APAC (coupled with large diabetic & pre-diabetic patient population), strengthening distribution networks of global product manufacturers in the region, evolving regulatory framework for marketing approvals & medical reimbursements, continued expansion of advanced medical facilities in emerging countries (such as China & India), and rising public awareness related to benefits offered by human insulin in diabetes treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Insulin market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Insulin Analogs and Biosimilars
Human Insulin Biologics

Segmentation by application
Short Acting
Intermediate Acting
Long Acting
Pre-Mix Insulin

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
B. Braun
Becton, Dickinson
Biocon
Biodel
ELI Lilly
Julphar
NOVO Nordisk
Sanofi
Wockhardt
Ypsomed

Key Questions Addressed in this Report

What is the 10-year outlook for the global Human Insulin market?

What factors are driving Human Insulin market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Human Insulin market opportunities vary by end market size?

How does Human Insulin break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.